[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545389":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":21,"locations":26,"responsibleParty":50,"collaborators":7,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":7,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":7,"enrollmentInfo":62,"targetDuration":7,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Xijing Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"PROCEDURE","Transcatheter aortic valve replacement","A total of 500 consecutive patients with NAVR undergoing TAVR will be enrolled at 3-5 centers. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years",[14],"Transcatheter aortic valve implantation",[16,19],{"name":17,"affiliation":5,"role":18},"Ling Tao, M.D, Ph.D","STUDY_CHAIR",{"name":20,"affiliation":5,"role":18},"Rutao Wang, M.D, Ph.D",[22],{"name":20,"role":23,"phone":24,"phoneExt":7,"email":25},"CONTACT","+86-15091095796","rutaowang@qq.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Xi'an","Shannxi","710032","China","CN",{"type":35,"coordinates":36},"Point",[37,38],108.92861,34.25833,{"lat":38,"lon":37},[41,43,47],{"name":42,"role":23,"phone":24,"phoneExt":7,"email":25},"Rutao Wang, M.D., Ph.D.",{"name":44,"role":23,"phone":45,"phoneExt":7,"email":46},"Ruining Zhang, BSc","+86-15802990370","ruining-zhang@qq.com",{"name":48,"role":49,"phone":7,"phoneExt":7,"email":7},"Ling Tao, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"LingTao","Professor in Cardiology, Director of the department of Cardiology","100545389","transcatheter-aortic-valve-replacement-for-pure-severe-aortic-valve-regurgitation-100545389",false,"NCT06381271","Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation","Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation: a Real-world, Prospective, Multicenter Study (TRUST TAVR Registry)","Inclusion Criteria:\n\n* 1\\. Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.\n* 2\\. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form\n\nExclusion Criteria:\n\n* 1\\. Patients who cannot provide informed consent\n* 2\\. Patients who are treated with TAVR for aortic stenosis\n* 3\\. Patients who are participating in other clinical trials","ALL","18 Years",{"count":63,"type":64},500,"ESTIMATED","OBSERVATIONAL","The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected",[68],"Aortic Valve Regurgitation",[68,70,71],"TAVR","Real-Word","2024-04-18",{"date":74,"type":75},"2024-04-24","ACTUAL",{"date":77,"type":75},"2018-10-30",{"date":79,"type":64},"2034-10",{"name":5,"class":6},1]